NCT07543471 A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer Status NOT_YET_RECRUITING Phase PHASE1
NCT07502014 A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07446322 FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Status RECRUITING Phase PHASE2
NCT07116577 Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC Status NOT_YET_RECRUITING Phase PHASE2
NCT06980454 Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06829355 "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" Status RECRUITING Phase PHASE2
NCT05690035 Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer Status WITHDRAWN Phase PHASE2
NCT05127759 The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation Status UNKNOWN Phase PHASE2
NCT03567629 Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer Status UNKNOWN Phase PHASE2